NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

停經後骨質疏鬆症市場:2020∼2026年

Postmenopausal Osteoporosis Market 2020-2026

出版商 Orion Market Research Pvt Ltd 商品編碼 1008113
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
停經後骨質疏鬆症市場:2020∼2026年 Postmenopausal Osteoporosis Market 2020-2026
出版日期: 2021年05月04日內容資訊: 英文
簡介

在預測期內,全球絕經後骨質疏鬆症市場預計將以約 3.6% 的複合年增長率增長。促進市場增長的因素包括骨質疏鬆症患病率的增加和新興經濟體醫療基礎設施的改善。人們依賴吸煙和飲酒的生活方式改變、對該疾病認識的提高、藥物進化和 FDA 批准也推動了市場增長。此外,產品審批和監管過程中的高標準、與仿製藥的競爭、專利到期都會阻礙市場增長。新應用的開發、產品設計的創新以及各個市場參與者的地域擴張為市場增長創造了機會。。

本報告提供停經後骨質疏鬆症市場相關調查,提供市場概要,以及不同治療,各流通管道,各地區的趨勢,及加入此市場的主要企業的簡介等資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

  • 調查範圍
  • 分析師的洞察和目前市場趨勢
  • 規則

第3章 競爭情形

  • 主要企業分析
    • 概要
    • 財務分析
    • SWOT分析
  • 重要的策略分析
  • COVID-19對主要參與者的影響

第4章 市場決策要素

  • 動機
  • 阻礙因素
  • 市場機會

第5章 市場細分化

  • 全球停經後骨質疏鬆症市場,不同治療
    • 雙磷酸鹽
    • 荷爾蒙
    • 雷奈酸鍶
    • 其他(配體抑製劑)
  • 全球停經後骨質疏鬆症市場,各流通管道
    • 醫院藥局
    • 零售藥局
    • 電子商務藥局

第6章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他
  • 其他地區

第7章 企業簡介

  • Allergan Plc
  • Amgen Inc.
  • Biologicsmd, Inc.
  • Eli Lilly And Co.
  • F. Hoffmann-La Roche Ltd.
  • Glaxosmithkline Plc
  • Ligand Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Novo Nordisk Inc.
  • Outlook Therapeutics, Inc.
  • Paras Biopharmaceuticals Finland Oy
  • Pfizer Inc.
  • Phytohealth Corp.
  • Procter & Gamble Co.
  • Radius Health Inc.
  • Sanofi S.A.
  • Tarsa Therapeutics, Inc.
  • Teva Pharmaceuticals Industries Ltd.
目錄
Product Code: OMR2023406

Global Postmenopausal Osteoporosis Market Size, Share & Trends Analysis Report by Treatment (Bisphosphonates, Hormones, Strontium Ranelate, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce Pharmacies) Forecast 2021-2027

The global postmenopausal osteoporosis market is anticipated to grow at a CAGR of around 3.6% during the forecast period. Osteoporosis is a form of disorder caused by skeletal fragility, low bone mass, and microarchitectural. It results in a condition where bone mass and bone density decrease that may increase the chances of bone fracture in long run. The factors contributing to the growth of the market include the growing prevalence of osteoporosis and improvement in healthcare infrastructure in emerging economies. Additionally, changing lifestyles where people are addicted to smoking and alcohol and increasing awareness among people regarding the disorder and advancement in drugs and approval by the FDA is also driving the growth of the market. Moreover, the higher standards approval regulation process of products, rising generic competition, and patent expiration will be hampering the growth of the market. Moreover, new application developments and innovation in product designs and geographic expansions by various market players are creating an opportunity for market growth.

Segmental Outlook

The global postmenopausal osteoporosis market is segmented based on the treatment and distribution channel. Based on treatment, the market is segmented into bisphosphonates, hormones, strontium ranelate, and others. Further on the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, e-commerce pharmacies.

Global Postmenopausal Osteoporosis Market Share by Treatment, 2020 (%)

Source: OMR Global

The bisphosphonates segment is projected to have a significant share in the global Postmenopausal Osteoporosis Market

Among treatment, the bisphosphonates segment projected to have a considerable share in the market. These are a group of drugs that treats slowing bone loss. It also reduces the risk of hip and spine fractures in osteoporosis. These are used at different doses that support in treating Paget's disease of bone. Bisphosphonates are usually well tolerated by patients and the risk of digestive problems with oral preparations is reduced while taken carefully following the instructions. It has very few side effects including, a sore mouth, muscle pain, headaches, flu, bone pain, and others. People with severe kidney problems, pregnant women, people who are taking parathyroid hormone currently, and people with esophagitis cannot take bisphosphonates. Different types of bisphosphonates include ibandronic acid, zoledronic acid, sodium clodronate, and disodium pamidronate. The various advantages of bisphosphonates include it prevents bone loss, improves bone strength and preserves the bone structure, and reduces the fracture risks in patients with osteoporosis.

Regional Outlooks

The global postmenopausal osteoporosis market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. North America is projected to dominate the market during the forecast period of 2021 followed by Europe attributed to factors such as early adoption rates of treatments, growing aged population who more have chances of the osteoporosis disease. Whereas Europe has been considered as the second largest region attributing to factors such as high diagnostic rates and better healthcare infrastructure in the region.

Global Postmenopausal Osteoporosis Market Growth, by Region 2021-2027

Source: OMR Global

Asia-Pacific will have considerable growth in the global postmenopausal osteoporosis market

Asia-Pacific is projected to grow at a significant CAGR in the postmenopausal osteoporosis market during the forecast period. The growth is attributed to increasing healthcare spending and improvement in healthcare infrastructure in the region. The simultaneous development in the medical tourism industry in the following industry also propelling the market growth. Major players including Eily Lily and Co, Pfizer Inc, Protector& Gamble are also having their operation in the region and contributing significantly to the growth of the market.

Market Players Outlook

The key players of the postmenopausal osteoporosis market include Eli Lilly and CO., Pfizer Inc., Proctor & Gamble Co., Amgen Inc., Novartis International AG, Allergan plc, and others. The market players are considerably contributing to the market growth by adopting various strategies including mergers, and acquisitions, collaborations, and new product launches. For instance, in December 2018, GlaxoSmithKline plc and TESARO Inc announced that GSK will be acquiring TESARO that is an oncology-focused company. This acquisition will be strengthening GSK pharmaceutical business along with accelerating the GSK pipeline and its commercial capability in the oncology business.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global Postmenopausal Osteoporosis market.

Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Postmenopausal Osteoporosis Industry
  • Recovery Scenario of Global Postmenopausal Osteoporosis Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Regulations

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
  • 3.2. Key strategy Analysis
  • 3.3. Impact of COVID-19 on key players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Postmenopausal Osteoporosis marketbyTreatment
    • 5.1.1. Bisphosphonates
    • 5.1.2. Hormones
    • 5.1.3. Strontium Ranelate
    • 5.1.4. Others (Rank Ligand Inhibitors)
  • 5.2. Global Postmenopausal Osteoporosis marketby Distribution Channel
    • 5.2.1. Hospital Pharmacies
    • 5.2.2. Retail Pharmacies
    • 5.2.3. E- Commerce Pharmacies

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Allergan Plc
  • 7.2. Amgen Inc.
  • 7.3. Biologicsmd, Inc.
  • 7.4. Eli Lilly And Co.
  • 7.5. F. Hoffmann-La Roche Ltd.
  • 7.6. Glaxosmithkline Plc
  • 7.7. Ligand Pharmaceuticals, Inc.
  • 7.8. Merck & Co., Inc.
  • 7.9. Novartis International AG
  • 7.10. Novo Nordisk Inc.
  • 7.11. Outlook Therapeutics, Inc.
  • 7.12. Paras Biopharmaceuticals Finland Oy
  • 7.13. Pfizer Inc.
  • 7.14. Phytohealth Corp.
  • 7.15. Procter & Gamble Co.
  • 7.16. Radius Health Inc.
  • 7.17. Sanofi S.A.
  • 7.18. Tarsa Therapeutics, Inc.
  • 7.19. Teva Pharmaceuticals Industries Ltd.

LIST OF TABLES

  • 1. GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKETRESEARCH AND ANALYSIS BY TREATMENT,2020-2027 ($ MILLION)
  • 2. GLOBALBISPHOSPHONATESMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 3. GLOBAL HORMONESMARKETRESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 4. GLOBALSTRONTIUM RANELATEMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)

5. GLOBALPOSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL,

  • 6. GLOBAL POSTMENOPAUSAL OSTEOPOROSIS FOR HOSPITAL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION2020-2027($ MILLION)
  • 7. GLOBAL POSTMENOPAUSAL OSTEOPOROSIS FORRETAIL PHARMACIESMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 8. GLOBAL POSTMENOPAUSAL OSTEOPOROSIS FORE-COMMERCE PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 10. NORTH AMERICAN POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 11. NORTH AMERICAN POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT,2020-2027 ($ MILLION)
  • 12. NORTH AMERICAN POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL,2020-2027 ($ MILLION)
  • 13. EUROPEAN POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 14. EUROPEAN POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT,2020-2027 ($ MILLION)
  • 15. EUROPEAN POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 16. ASIA-PACIFIC POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 17. ASIA-PACIFIC POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT,2020-2027 ($ MILLION)
  • 18. ASIA-PACIFIC POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 19. REST OF THE WORLD POSTMENOPAUSAL OSTEOPOROSIS MARKE TRESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 20. REST OF THE WORLD POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT,2020-2027 ($ MILLION)
  • 21. REST OF THE WORLD POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)

LIST OF FIGURES

1. IMPACT OF COVID-19 ON GLOBAL POSTMENOPAUSAL OSTEOPOROSISMARKET, 2020-2027 (% MILLION)

2. IMPACT OF COVID-19 ON GLOBAL POSTMENOPAUSAL OSTEOPOROSISMARKET BY SEGMENT, 2020-2027 (% MILLION)

  • 3. RECOVERY OF GLOBAL POSTMENOPAUSAL OSTEOPOROSISMARKET, 2020-2027 (%)
  • 4. GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKETSHARE BY TREATMENT,2020 VS 2027 (%)
  • 5. GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKETSHARE BY DISTRIBUTION CHANNEL, 2020 VS 2027 (%)
  • 6. GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKETSHARE BYMATERIAL, 2020 VS 2027 (%)
  • 7. GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKETSHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 8. GLOBAL BISPHOSPHONATESMARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 9. GLOBAL HORMONESMARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 10. GLOBAL STRONTIUM RANELATEMARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 11. GLOBALHOSPITAL PHARMACIESMARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 12. GLOBALRETAIL PHARMACIESMARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 13. GLOBAL E- COMMERCE PHARMACIES MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 14. US POSTMENOPAUSAL OSTEOPOROSIS MARKETSIZE, 2020-2027($ MILLION)
  • 15. CANADA POSTMENOPAUSAL OSTEOPOROSIS MARKETSIZE, 2020-2027($ MILLION)
  • 16. UK POSTMENOPAUSAL OSTEOPOROSIS MARKET SIZE, 2020-2027($ MILLION)
  • 17. FRANCE POSTMENOPAUSAL OSTEOPOROSIS MARKETSIZE, 2020-2027($ MILLION)
  • 18. GERMANY POSTMENOPAUSAL OSTEOPOROSIS MARKETSIZE, 2020-2027($ MILLION)
  • 19. ITALY POSTMENOPAUSAL OSTEOPOROSIS MARKETSIZE, 2020-2027($ MILLION)
  • 20. SPAIN POSTMENOPAUSAL OSTEOPOROSIS MARKETSIZE, 2020-2027($ MILLION)
  • 21. REST OF EUROPE POSTMENOPAUSAL OSTEOPOROSIS MARKETSIZE, 2020-2027($ MILLION)
  • 22. INDIA POSTMENOPAUSAL OSTEOPOROSIS MARKETSIZE, 2020-2027($ MILLION)
  • 23. CHINA POSTMENOPAUSAL OSTEOPOROSIS MARKETSIZE, 2020-2027($ MILLION)
  • 24. JAPAN POSTMENOPAUSAL OSTEOPOROSIS MARKETSIZE, 2020-2027($ MILLION)
  • 25. SOUTH KOREA POSTMENOPAUSAL OSTEOPOROSIS MARKETSIZE, 2020-2027($ MILLION)
  • 26. REST OF ASIA-PACIFIC POSTMENOPAUSAL OSTEOPOROSIS MARKETSIZE, 2020-2027($ MILLION)
  • 27. REST OF THE WORLD POSTMENOPAUSAL OSTEOPOROSIS MARKETSIZE, 2020-2027($ MILLION)